Zuma 7 - crossover rate confirmed

Mar 23, 2023

In yesterday’s post, which you can read here, I commented about the poor rate of post progression CAR-T in the control arm of Zuma-7. Well a reader has come to the rescue to confirm this is true.

The Drug Development Letter

Zuma 7 has OS benefit... Not so fast.

Kite has made an announcement. Zuma-7, a randomized control trial of axicel versus auto transplant, has achieved an OS benefit. Let's be clear on who's in this study. It's patients with DLBCL who are primary refractory or those who relapsed within 12 months. Relapse within 12 months is not the same as relapse at 24 months. Moreover, we all know there's …

2 years ago · 11 likes · 1 comment · Vinay Prasad

This slide was presented at ASH. The lower left 59 is the problem in this study.

Zuma 7 - crossover rate confirmed

Discussion about this post